News Image

Exploring growth characteristics of ALKERMES PLC (NASDAQ:ALKS).

By Mill Chart

Last update: Apr 10, 2024

In this article we will dive into ALKERMES PLC (NASDAQ:ALKS) as a possible candidate for growth investing. Investors should always do their own research, but we noticed ALKERMES PLC showing up in our Louis Navellier growth screen, which makes it worth to investigate a bit more.

Exploring Why NASDAQ:ALKS Holds Promise for Growth Investors.

  • The Return on Equity(ROE) of ALKERMES PLC is 29.59%, which is a strong number. This indicates the company's ability to generate favorable returns for shareholders and reflects its effective management of resources.
  • ALKERMES PLC has surpassed EPS estimates 3 times in the last 4 quarters, reflecting its strong financial performance and effective management. This trend suggests the company's ability to generate positive earnings surprises and drive shareholder value.
  • With notable 1-year revenue growth of 49.61%, ALKERMES PLC exemplifies its ability to generate increased sales and revenue streams. This growth signifies the company's strong business performance and its potential for future growth.
  • With consistent quarter-to-quarter (Q2Q) revenue growth of 23.88%, ALKERMES PLC exemplifies its ability to generate increased sales and revenue streams. This growth signifies the company's strong business performance and its potential for continued growth.
  • With positive growth in its operating margin over the past year, ALKERMES PLC showcases its ability to improve profitability through effective cost control and operational efficiency. This growth underscores the company's commitment to enhancing its financial performance.
  • ALKERMES PLC has experienced notable growth in its free cash flow (FCF) over the past year, signaling improved cash generation and strong financial performance. This growth suggests the company's ability to generate excess cash for reinvestment or shareholder returns.
  • The quarterly earnings of ALKERMES PLC have shown a 57.14% increase compared to the previous quarter, as revealed in the recent financial report. This growth signifies positive momentum in the company's financials, pointing towards a promising upward trend
  • The average next Quarter EPS Estimate for ALKERMES PLC has experienced a 24.07% change in the last 3 months, reflecting evolving expectations by analysts regarding the company's EPS performance.
  • In the most recent financial report, ALKERMES PLC reported a 57.14% increase in quarterly earnings compared to the previous quarter. This notable growth indicates positive momentum in the company's financials, suggesting an upward trend
  • accelerating EPS growth for ALKERMES PLC: the current Q2Q growth of 57.14% exceeds the previous year Q2Q growth of -39.13%.

What else is there to say on the fundamentals of NASDAQ:ALKS?

ChartMill assigns a Fundamental Rating to every stock. This score ranges from 0 to 10 and is updated daily. The score is determined by evaluating multiple fundamental indicators and properties.

Overall ALKS gets a fundamental rating of 6 out of 10. We evaluated ALKS against 589 industry peers in the Biotechnology industry. ALKS is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. ALKS scores decently on growth, while it is valued quite cheap. This could make an interesting combination. This makes ALKS very considerable for value investing!

Check the latest full fundamental report of ALKS for a complete fundamental analysis.

More growth stocks can be found in our Lois Navellier screen.

Disclaimer

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.

Back

ALKERMES PLC

NASDAQ:ALKS (5/24/2024, 7:13:31 PM)

After market: 24.02 0 (0%)

24.02

+0.02 (+0.08%)

ALKS News

News Image2 days ago - InvestorPlace3 Biotech Stocks That Could Be Millionaire-Makers: May Edition

Investors should take a close look at these biotech stocks as they position themselves to provide high returns.

News Image10 days ago - Market News VideoALKS July 19th Options Begin Trading
News Image13 days ago - Alkermes plcAlkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of research related to its psychiatry franchise products—LYBALVI® (olanzapine and...

News Image19 days ago - ChartmillInvestors should take notice of NASDAQ:ALKS—it offers a great deal for the fundamentals it presents.

ALKERMES PLC (NASDAQ:ALKS) is probably undervalued for the fundamentals it is displaying.

News Image25 days ago - Alkermes plcAlkermes plc Completes Sale of Athlone, Ireland Facility to Novo Nordisk

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) has completed the previously announced sale of its development and manufacturing facility in Athlone, Ireland to...

News Image26 days ago - InvestorPlaceALKS Stock Earnings: Alkermes Misses EPS, Misses Revenue for Q1 2024

ALKS stock results show that Alkermes missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

News Imagea month ago - Alkermes plcAlkermes Announces Initiation of Vibrance-1 Phase 2 Study Evaluating ALKS 2680 for the Treatment of Narcolepsy Type 1

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced initiation of the Vibrance-1 study, a phase 2 clinical trial evaluating the safety and efficacy of...

News Imagea month ago - Market News VideoFirst Week of June 21st Options Trading For Alkermes (ALKS)
News Imagea month ago - Alkermes plcAlkermes to Report First Quarter Financial Results on May 1, 2024

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, May 1, 2024 to...

News Image2 months ago - Market News VideoOversold Conditions For Alkermes (ALKS)
News Image2 months ago - Alkermes plcAlkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research Society

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the oral presentation of clinical data at the 2024 Congress of the Schizophrenia International...

News Image2 months ago - Market News VideoNoteworthy Tuesday Option Activity: ALKS, DKNG, VRT
ALKS Links
Follow us for more